Literature DB >> 8144398

In vivo efficacy of neocarzinostatin coupled with Fab human/mouse chimeric monoclonal antibody A7 against human colorectal cancer.

T Yamaguchi1, H Tsurumi, T Kotani, N Yamaoka, E Otsuji, K Kitamura, T Takahashi.   

Abstract

The anticancer polypeptide neocarzinostatin (NCS) was covalently coupled to a human/mouse chimeric Fab A7 monoclonal antibody (chFabA7) and the in vivo efficacy of this conjugate was examined. NCS concentration assay was carried out, and acute toxicity and tumoricidal effects were examined. The concentration assay, using anti-NCS monoclonal antibody, revealed that administration of the chA7Fab conjugate leads to a greater blood retention and a higher tumor accumulation of NCS, when compared to free NCS administration. The tumoricidal effect of chA7Fab-NCS was higher than that of either free NCS or the saline control, against antigen-positive tumors. In antigen-negative tumors there was no difference in toxic effect among the three preparations. Values of LD50, reflecting acute toxicity, were 5050 U/kg and 3600 U/kg for the chA7Fab-NCS and the free NCS, respectively. These results suggest that chFabA7-NCS may be a promising tool for targeting cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144398      PMCID: PMC5919422          DOI: 10.1111/j.1349-7006.1994.tb02078.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  13 in total

1.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

2.  Disposition characteristics of mitomycin C-dextran conjugate in normal and tumor-bearing muscles of rabbits.

Authors:  R Atsumi; K Endo; T Kakutani; Y Takakura; M Hashida; H Sezaki
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

3.  Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts.

Authors:  H Sands; P L Jones; S A Shah; D Palme; R L Vessella; B M Gallagher
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

4.  Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications.

Authors:  J C Reynolds; S Del Vecchio; H Sakahara; M E Lora; J A Carrasquillo; R D Neumann; S M Larson
Journal:  Int J Rad Appl Instrum B       Date:  1989

5.  Immunochemical characterization of the antigen recognized by the murine monoclonal antibody A7 against human colorectal cancer.

Authors:  K Kitamura; T Takahashi; T Yamaguchi; T Yokota; A Noguchi; T Amagai; J Imanishi
Journal:  Tohoku J Exp Med       Date:  1989-02       Impact factor: 1.848

6.  Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particles. Clinical trials.

Authors:  A Hagiwara; T Takahashi; R Lee; T Ueda; M Takeda; T Itoh
Journal:  Cancer       Date:  1987-01-15       Impact factor: 6.860

7.  Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.

Authors:  D E Milenic; T Yokota; D R Filpula; M A Finkelman; S W Dodd; J F Wood; M Whitlow; P Snoy; J Schlom
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

8.  The role of monoclonal antibody A7 as a drug modifier in cancer therapy.

Authors:  K Kitamura; T Miyagaki; N Yamaoka; H Tsurumi; A Noguchi; T Yamaguchi; T Takahashi
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

9.  Comparative imaging and biodistribution studies with an anti-CEA monoclonal antibody and its F(ab)2 and Fab fragments in mice with colon carcinoma xenografts.

Authors:  S M Andrew; M V Pimm; A C Perkins; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1986

10.  Monoclonal antibody A7 tumor localization enhancement by its F(ab')2 fragments to colon carcinoma xenografts in nude mice.

Authors:  K Kitamura; T Takahashi; T Yamaguchi; S Kitai; T Amagai; J Imanishi
Journal:  Jpn J Clin Oncol       Date:  1990-06       Impact factor: 3.019

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.